Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Quidel Corporation has 3 pending office actions in Biotechnology & Pharmaceuticals. Those matters are distributed among 3 distinct examiners and 3 distinct art units, indicating that the current prosecution activity spans separate examination assignments.
NGUYEN, HENRY H is the busiest examiner, with 1 pending matter. Because the busiest examiner accounts for only 1 action, the record does not indicate concentration with a single examiner. Counsel should therefore track examiner-specific issues separately.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, HENRY H | 1 | 63.5% | +36.7% |
| DEVI, SARVAMANGALA | 1 | 65.5% | +55.5% |
| TRAN, CHAU NGUYEN BICH | 1 | 31.6% | +45.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18307749 | EXTRACTION REAGENT FOR USE IN AN ASSAY FOR DETECTION OF GROUP A STREPTOCOCCUS | DEVI, SARVAMANGALA | 9d overdue |
| 18571173 | METHOD TO IDENTIFY INDIVIDUALS WITH T CELL IMMUNITY TO SPECIFIC INFECTIOUS AGENTS | NGUYEN, HENRY H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18307749 | EXTRACTION REAGENT FOR USE IN AN ASSAY FOR DETECTION OF GROUP A STREPTOCOCCUS | DEVI, SARVAMANGALA | 9d overdue |
| 18571173 | METHOD TO IDENTIFY INDIVIDUALS WITH T CELL IMMUNITY TO SPECIFIC INFECTIOUS AGENTS | NGUYEN, HENRY H | — |
| 16817010 | RESULT DETERMINATION IN AN IMMUNOASSAY BY MEASURING KINETIC SLOPES | TRAN, CHAU NGUYEN BICH | — |
| Art Unit | Apps |
|---|---|
| 1758 | 1 |
| 1645 | 1 |
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18571173 | METHOD TO IDENTIFY INDIVIDUALS WITH T CELL IMMUNITY TO SPECIFIC INFECTIOUS AGENTS | NGUYEN, HENRY H | 1758 | §103§112 | Final Rejection | — | Pending | Dec 15, 2023 |
| 18307749 | EXTRACTION REAGENT FOR USE IN AN ASSAY FOR DETECTION OF GROUP A STREPTOCOCCUS | DEVI, SARVAMANGALA | 1645 | §103§112 | Final Rejection | 9d overdue | Pending | Apr 26, 2023 |
| 16817010 | RESULT DETERMINATION IN AN IMMUNOASSAY BY MEASURING KINETIC SLOPES | TRAN, CHAU NGUYEN BICH | 1677 | §103 | Non-Final OA | — | Pending | Mar 12, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQuidel Corporation has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Henry H Nguyen has the most, with 1 of Quidel Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
